Gyre Therapeutics, Inc. (GYRE) Stock

Gyre Therapeutics, Inc. (GYRE) is a Healthcare stock trading at $6.24 (as of 2026-06-18), with a market capitalization of $573.44M and a trailing P/E of -78.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for organ fibrosis, including anti-inflammatory and anti-fibrotic therapies. It markets ETUARY (pirfenidone) for idiopathic pulmonary fibrosis and advances additional candidates in clinical development for conditions such as interstitial lung diseases, hepatitis B–related liver fibrosis, and liver and pulmonary disorders.

Valuation — source: SEC EDGAR (first-party)
Price	$6.24
Market Cap	$573.44M
P/E Ratio	-78.1
EV / EBITDA	229.7
Price / Book	4.43
Price / Sales	5.18
DCF Value (model)	$0.35
DCF Upside vs Price	-94.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$116.59M
Net Margin	8.5%
Return on Equity	-2.7%
Current Ratio	4.64
Revenue Growth (YoY)	10.2%
EPS Growth (YoY)	-57.1%
FCF Growth (YoY)	-97.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	16.18 (safe)

Valuation vs Sector & Industry
Stock P/E	-78.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-474.0%
vs Industry	-559.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($8.48M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ping Zhang
Employees	579
Country	US
IPO Date	2006-04-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.